Skip to main content
. Author manuscript; available in PMC: 2009 Dec 15.
Published in final edited form as: Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014

Fig. 3.

Fig. 3

Activation of Akt has no effect on proliferation and does not affect response to erlotinib. (A to C) LN229:EGFR cells were transduced with activated myristoylated Akt (Myr-Akt) and treated as indicated. Viability (WST-1 assay) and flow cytometric analyses (A and B) confirmed that Myr-Akt had negligible effects on cell viability and proliferation and did not affect response to erlotinib. (P > 0.05 by Student's t test for vector-transduced cells versus Myr-Akt-transduced cells in response to erlotinib. Data shown are means ± SDs for quadruplicate measurements). (C) Myr-Akt diminished the ability of erlotinib to block Akt phosphorylation at both Ser473 and Ser308, but had no effect on abundance of p-rpS6. A blot representative of two independent experiments is shown. Erlotinib dosage was 5 μM in all experiments.